Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-02T22:00:07.944Z Has data issue: false hasContentIssue false
  • English
  • Français

Once Weekly Pimozide versus Fluphenazine Decanoate as Maintenance Therapy in Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

R. Mccreadie ,
M. Mackie ,
D. Morrison  and
J. Kidd
R. Mccreadie
Affiliation:
Crichton Royal Hospital, Dumfries, DG1 4TG
M. Mackie
Affiliation:
Dumfries and Galloway Royal Infirmary, Dumfries, DG1 4AP
D. Morrison
Affiliation:
Crichton Royal Hospital, Dumfries, DG1 4TG
J. Kidd
Affiliation:
Gartnavel Royal Hospital, Glasgow, G12 0XH (Crichton Royal Hospital, Dumfries)
Get access Rights & Permissions [Opens in a new window]

Summary

In a double blind trial, 28 male chronic schizophrenic in-patients received either pimozide, given once weekly, or fluphenazine decanoate, given mostly once fortnightly. There was no difference in relapse rates over nine months. However, three-quarters of the patients on pimozide who completed the trial developed at least mild tardive dyskinesia. All patients on pimozide lost weight, the average loss being 5.4 kg (12 lbs). Plasma pimozide levels suggested satisfactory drug compliance. Plasma prolactin levels confirmed that in the pimozide group there was fluctuating dopamine receptor antagonism, while in the fluphenazine group average plasma prolactin levels throughout most of the interval between injections were at the upper limit of normal.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 140 , Issue 3 , March 1982 , pp. 280 - 286
Copyright
Copyright © Royal College of Psychiatrists, 1982 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anonymous (1974) British Medical Journal, i, 168.Google Scholar
Crane, G. E. (1973) Persistent dyskinesia. British Journal of Psychiatry, 122, 395–405.CrossRefGoogle ScholarPubMed
Falloon, I., Watt, D. C. & Shepherd, M. (1978a) A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychological Medicine, 8, 59–60.CrossRefGoogle ScholarPubMed
Falloon, I., Watt, D. C. & Shepherd, M. (1978b) The social outcome of patients in a trial of long term continuation therapy in schizophrenia: pimozide versus fluphenazine. Psychological Medicine, 8, 265–74.Google Scholar
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munos, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 57–63.CrossRefGoogle ScholarPubMed
Griffiths, R. D. P. (1973) A standardized assessment of the work behaviour of psychiatric patients. British Journal of Psychiatry, 123, 463–8.CrossRefGoogle ScholarPubMed
Hamilton, M., Smith, A. L. G., Lapidus, H. E. & Cadogan, E. P. (1960) A controlled trial of thiopropazate dihydrochloride (Dartalan) chlorpromazine and occupational therapy in chronic schizophrenics. Journal of Mental Science, 106, 40–55.CrossRefGoogle ScholarPubMed
Jeste, D. V., Potkin, S. G., Sinha, S., Feder, S. & Wyatt, R. J. (1979) Tardive dyskinesia—reversible and persistent. Archives of General Psychiatry, 36, 585–90.CrossRefGoogle ScholarPubMed
Johnson, D. A. W. (1981) Studies of depressive symptoms in schizophrenia. British Journal of Psychiatry, 139, 89–101.CrossRefGoogle ScholarPubMed
Kemsley, W. F. F. (1952) Body weight at different ages and heights. Annals of Eugenics, 16, 316–34.Google ScholarPubMed
Krawiecka, M., Goldberg, D. & Vaughan, M. (1977) A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica, 55, 299–308.CrossRefGoogle ScholarPubMed
Leff, J. & Vaughn, C. (1980) The interaction of life events and relatives expressed emotion in schizophrenia and depressive neurosis. British Journal of Psychiatry, 136, 146–53.CrossRefGoogle ScholarPubMed
McCreadie, R. G., Heykants, J. J. P., Chalmers, A. & Anderson, A. M. (1979) Plasma pimozide profiles in chronic schizophrenics. British Journal of Clinical Pharmacology, 7, 533–4.CrossRefGoogle ScholarPubMed
McCreadie, R. G., Dingwall, J. M., Wiles, D. H. & Heykants, J. J. P. (1980) Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry, 137, 510–17.CrossRefGoogle ScholarPubMed
Michiels, L. J. M., Heykants, J. J. P., Knaeps, A. G. & Janssen, P. A. J. (1975) Radioimmunoassay of the neuroleptic drug pimozide. Life Sciences, 16, 937–44.CrossRefGoogle ScholarPubMed
Paykel, E. S., Mueller, P. S. & de la Vergne, P. M. (1973) Amitriptyline, weight gain, and carbohydrate craving: a side effect. British Journal of Psychiatry, 123, 501–7.CrossRefGoogle ScholarPubMed
Renton, C. A., Affleck, J. W., Carstairs, G. M. & Forrest, A. D. (1963) A follow up of schizophrenic patients in Edinburgh. Acta Psychiatrica Scandinavica, 39, 548–81.CrossRefGoogle ScholarPubMed
Siegel, S. (1956) Non-parametric Statistics for the Behavioural Sciences. New York: McGraw Hill.Google Scholar
Wing, J. K. (1961) A simple and reliable sub-classification of chronic schizophrenia. Journal of Mental Science, 107, 862–75.CrossRefGoogle Scholar
Wistedt, B., Wiles, D. & Kolakowska, T. (1981) Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet, i, 1163.CrossRefGoogle Scholar
Wyatt, R. J. & Torgow, J. S. (1977) A comparison of equivalent clinical potencies of neuroleptics as used to treat schizophrenia and affective disorders. Journal of Psychiatric Research, 13, 91–8.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.